BEACOPP or BEACOPP(ESC)  
(bleomycin-etoposide-DOXOrubicin-cyclophosphamide-vinCRITine-procarbazine-predniSONE)*  
*drug in italics is IV drug given in hospital or cancer centre

Diagnosis: Lymphoma

Clinical Verification
- Bloodwork and other clinical parameters have been verified by a regulated health professional  
  Date: ___________________________  
  Print name: ___________________________  
  Signature: ___________________________
- Prescription has been verified by a nurse or pharmacist  
  Date: ___________________________  
  Print name: ___________________________  
  Signature: ___________________________

Rx (Start Date/Day 1: _______)

Procarbazine 100 mg/m² x BSA x ____% dose* = __________ mg PO on Days 1 to 7
  Mitte: _________ x 50mg capsules (ODB general benefit)

AND

PredniSONE 40 mg/m² x BSA x ____% dose* = __________ mg PO daily in the morning with food on Days 1 to 14  
  Mitte: ___________ (ODB general benefit)

*Dose modification for:  □ Age/performance status   □ Hematologic toxicity □ Hepatic function □ Renal function  
  □ Other ___________________________

NO Repeats

Supportive Care Rx

□ 5-HT₆ receptor antagonist (centre choice) daily on Day(s)_____ Mitte: _______ Repeat:____ LU Code______

□ Dexamethasone 8mg PO daily on Days) _____ Mitte: _______ Repeat:____

□ G-CSF support, if applicable (specify drug, dose, frequency, duration):__________________________________________________________  
  Mitte: _______ Repeat:____  □ LU Code _________

Allergies (also specify reaction)  □ None known

Prescriber information (name, office phone number/fax, address if different than hospital address)  
  ___________________________

Pharmacist information (name, office phone number/fax)  
  ___________________________

Date: ___________________________  
  Print name: ___________________________  
  Physician Signature: ___________________________  
  CPSO#: ___________________________
OPTIONAL INFORMATION

☐ Patient has been counseled by an Oncology Pharmacist

<table>
<thead>
<tr>
<th>Print name</th>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
</table>

OR

☐ Requires counseling
☐ Drug interaction assessment

Drug-specific information
For the complete information, please refer to the Cancer Care Ontario drug information sheets available at www.cancercare.on.ca/drugformulary